PMID-sentid	Pub_year	Sent_text		comp_official_name	comp_offsetprotein_name	organism	prot_offset
14663007-5	2003	Importantly, the selective A2A antagonist KW6002 reverses motor disability and increases locomotor activity in MPTP-treated primates without provoking dyskinesia established by previous exposure to L-dopa.	istradefylline	42-48	spectrin, alpha, non-erythrocytic 1	Rattus norvegicus	27-30	
17467309-0	2007	The effect of striatal dopamine depletion and the adenosine A2A antagonist KW-6002 on reversal learning in rats.	istradefylline	75-82	spectrin, alpha, non-erythrocytic 1	Rattus norvegicus	60-63	
17310264-10	2007	KW-6002 and Biogen-34 exhibited the highest selectivity for A2A vs A1 (human and rat), respectively.	istradefylline	0-7	spectrin, alpha, non-erythrocytic 1	Rattus norvegicus	60-63	
17310264-16	2007	Among the six A2A-antagonists, KW-6002 is the best for use in in vivo animal studies, particularly for a CNS target, based on its bioavailability, half life, and brain penetration.	istradefylline	31-38	spectrin, alpha, non-erythrocytic 1	Rattus norvegicus	14-17	
14663007-7	2003	The data available suggest that A2A antagonists, such as KW6002, may be effective as monotherapy for the management of PD and that they will also produce additional benefit when administered in combination with L-dopa or dopamine agonist therapy.	istradefylline	57-63	spectrin, alpha, non-erythrocytic 1	Rattus norvegicus	32-35